



because every woman deserves to be sure

About half of all women have dense breast tissue.

This means they're about 5-times more likely to develop breast cancer in their lifetime. And because dense breast tissue camouflages cancer tissue on a mammogram — as much as 52% in very fibrous breasts — these women are also less likely to receive a potentially life-saving early diagnosis. Every woman deserves access to early detection.

That's why we developed Syantra DX | Breast Cancer.



effective detection for all women

What is Syantra DX | Breast Cancer?

Syantra DX is a diagnostic procedure that uses a small amount of blood, a conventional qPCR platform and proprietary data analysis software to detect breast cancer.


As a blood-based test, Syantra DX offers a rapid, economical, accurate method of breast cancer screening independent of tissue density or age. And because the test involves no exposure to radiation, it can be performed at any time and as many times as a health care provider and individual decide.

How effective is it?

Syantra DX has returned results of 92% prediction accuracy, 97% sensitivity and 86% specificity from 738 pre-biopsy samples. We are currently engaged in clinical studies in Manchester, UK, Calgary, Canada and Oklahoma City, USA and are poised to begin trials in Seoul, South Korea. We have taken steps to ensure that once validated, the necessary regulatory approvals will be obtainable using results collected through our current work.

How does the test work?

- 1) A patient goes for a routine blood draw.
- 2) A small blood sample is collected in a Syantra-specified specimen tube which stabilizes the sample and prepares it for analysis.
- 3) In the diagnostic laboratory, samples are processed, and gene expression is determined with a Syantra-provided instrument platform and test components.
- 4) This information is then processed by Syantra using proprietary quality control and data analysis methodologies.
- 5) A report is generated. It contains test results, an indicator of confidence in those results and a summary of quality control checks. This is sent back to the ordering clinic or physician for patient follow-up.



Who is Syantra Inc.?

Syantra is a privately held company from Calgary, Alberta. Our exceptional, multidisciplinary team is comprised of clinicians, bioengineers, data scientists, laboratory scientists, regulatory experts and business development professionals.

Syantra Inc.
125B – 50 Collegiate Place NW
Calgary, AB
T2N 1N4 Canada
syantra.com

Key partners & associates:

Manchester University
NHS Foundation Trust (UK)
NorthWest EHealth (UK)
University of Calgary (Canada)
Alberta Cancer Foundation (Canada)
Alberta Innovates (Canada)
DynalIFE Medical Labs (Canada)
Yonsei University (South Korea)

Contact us:

Bob Shepherd
President & CEO
bob.shepherd@syantra.com
T. +1 403 629 4404

Terry Macartney
Vice President Business Development
terry.macartney@syantra.com
T. +1 403 560 1714

